In the neutrophilic asthma model, treatment with DNase I or CI-amidine can reduce the expression of MPO and CitH3, decrease airway hyperresponsiveness, alleviate the accumulation of inflammatory cells and mucus obstruction, and mitigate inflammation-induced damage. Here, MPO is linked to airway hyperresponsiveness.